CCR2 Targeted Molecular Imaging and Treatment of Abdominal Aortic Aneurysms

The purpose of this research study is to look at whether an investigational imaging agent, Cu-64 DOTA-ECL1i, used during PET/CT scanning, can help to identify conditions that place patients at an increased risk for AAA rupture. The study is also looking more closely at cellular, molecular and inflammatory properties of the aortic wall. Having the ability to identify markers that predict AAA progression/expansion and risk for rupture could allow the physician to manage patients in a more individualized, personal way. The aorta is the main artery that supplies blood flow from the heart to the rest of the body. It is approximately the size of a garden hose. Due to the effects of high blood pressure (hypertension), atherosclerosis (hardening of the arteries), and tobacco use, the aorta may widen and enlarge to form an aneurysm. An abdominal aortic aneurysm (AAA) is a dilation (enlargement or ballooning out) of a section of the aorta caused by disease or weakness in the aortic wall below the level of the kidney arteries. Currently, surgical repair or placement of an endovascular stent is the only treatment for AAA and there is no effective medication. Often patients remain without symptoms and are unaware that they have an AAA until their AAA ruptures, which carries a significant risk of death. For patients who are aware of their AAA, ultrasound and computed tomography (CT) scans are used to measure the size of the AAA in order to direct management strategies including the timing of repair.​

​Principal Investigator: Dr. Mohamed Zayed
Study Coordinator: Kelley Chadwick-Mansker


This study is currently enrolling participants. To learn more about CCR2 and how you can join contact our research office at (314) 289-7690

This is a joint study with the St. Louis VA and Washington University. ​
The Foundation funds this study through the NIH (National Institute of Health).